Sibylle Loibl
German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer
von Minckwitz G, Bauerfeind I, Clemens M, Schmidt M, Noeding S, Forstbauer H, Barinoff J, Belau A, Nekljudova V, Harbeck N, Lück H, Müller V, Kreienberg R, Möbus V, Schneeweiss A, Huober J, Thomssen C, Untch M, Jackisch C, Diel I, Elling D, Conrad B, Loibl S. German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer. J Clin Oncol 2013; 31:3531-9.
26.08.2013German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer
26.08.2013J Clin Oncol 2013; 31:3531-9
von Minckwitz Gunter, Bauerfeind Ingo, Clemens Michael, Schmidt Marcus, Noeding Stefanie, Forstbauer Helmut, Barinoff Jana, Belau Antje, Nekljudova Valentina, Harbeck Nadia, Lück Hans-Joachim, Müller Volkmar, Kreienberg Rolf, Möbus Volker, Schneeweiss Andreas, Huober Jens, Thomssen Christoph, Untch Michael, Jackisch Christian, Diel Ingo J, Elling Dirk, Conrad Bettina, Loibl Sibylle
Ki67 measured after neoadjuvant chemotherapy for primary breast cancer
von Minckwitz G, Fehm T, Barinoff J, Rüdiger T, Erbstoesser E, Fasching P, Karn T, Müller V, Jackisch C, Huober J, Hilfrich J, Tesch H, Schmitt W, Loibl S, Müller B, Blohmer J, Sinn B, Eidtmann H, Eiermann W, Gerber B, Denkert C. Ki67 measured after neoadjuvant chemotherapy for primary breast cancer. Clin Cancer Res 2013; 19:4521-31.
27.06.2013Ki67 measured after neoadjuvant chemotherapy for primary breast cancer
27.06.2013Clin Cancer Res 2013; 19:4521-31
von Minckwitz Gunter, Fehm Tanja, Barinoff Jana, Rüdiger Thomas, Erbstoesser Erhard, Fasching Peter A, Karn Thomas, Müller Volkmar, Jackisch Christian, Huober Jens, Hilfrich Jörn, Tesch Hans, Schmitt Wolfgang D, Loibl Sibylle, Müller Berit M, Blohmer Jens U, Sinn Bruno V, Eidtmann Holger, Eiermann Wolfgang, Gerber Bernd, Denkert Carsten
Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group
Lück H, Schuster T, Wollschläger K, Untch M, Thomssen C, Eidtmann H, Stickeler E, Richter B, Hubalek M, Jackisch C, Stähler A, Beckmann M, Heilmann V, Huober J, Schrader I, Loibl S, du Bois A, von Minckwitz G. Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group. Breast Cancer Res Treat 2013; 139:779-87.
15.06.2013Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group
15.06.2013Breast Cancer Res Treat 2013; 139:779-87
Lück Hans-Joachim, Schuster Tibor, Wollschläger Kerstin, Untch Michael, Thomssen Christoph, Eidtmann Holger, Stickeler Elmar, Richter Barbara, Hubalek Michael, Jackisch Christian, Stähler Ann, Beckmann Matthias, Heilmann Volker, Huober Jens, Schrader Iris, Loibl Sibylle, du Bois Andreas, von Minckwitz Gunter
Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44)
Huober J, Kümmel S, Mau C, Jackisch C, Khandan F, Costa S, Krabisch P, Loibl S, Nekljudova V, Untch M, Höß C, Gerber B, Fasching P, Hanusch C, Rezai M, Eidtmann H, Kittel K, Hilfrich J, Schwedler K, Blohmer J, Tesch H, Minckwitz G. Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44). Eur J Cancer 2013; 49:2284-93.
27.03.2013Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44)
27.03.2013Eur J Cancer 2013; 49:2284-93
Huober Jens, Kümmel Sherko, Mau Christine, Jackisch Christian, Khandan Fariba, Costa Serban Dan, Krabisch Petra, Loibl Sibylle, Nekljudova Valentina, Untch Michael, Höß Cornelia, Gerber Bernd, Fasching Peter A, Hanusch Claus, Rezai Mahdi, Eidtmann Holger, Kittel Kornelia, Hilfrich Jörn, Schwedler Kathrin, Blohmer Jens-Uwe, Tesch Hans, Minckwitz Gunter von
HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer
Denkert C, von Minckwitz G, Tesch H, Hansmann M, Reinisch M, Engels K, Sinn B, Fasching P, Mehta K, Solbach C, Brase J, Darb-Esfahani S, Kronenwett R, Prinzler J, Loibl S, Huober J, Untch M. HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer. Breast Cancer Res 2013; 15:R11.
07.02.2013HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer
07.02.2013Breast Cancer Res 2013; 15:R11
Denkert Carsten, von Minckwitz Gunter, Tesch Hans, Hansmann Martin-Leo, Reinisch Mattea, Engels Knut, Sinn Bruno V, Fasching Peter A, Mehta Keyur, Solbach Christine, Brase Jan C, Darb-Esfahani Silvia, Kronenwett Ralf, Prinzler Judith, Loibl Sibylle, Huober Jens, Untch Michael
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes
von Minckwitz G, Mehta K, Nekljudova V, Denkert C, Konecny G, Kaufmann M, Jackisch C, Huober J, Hilfrich J, Eiermann W, Gerber B, Fasching P, Eidtmann H, Costa S, Blohmer J, Untch M, Loibl S. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012; 30:1796-804.
16.04.2012Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes
16.04.2012J Clin Oncol 2012; 30:1796-804
von Minckwitz Gunter, Mehta Keyur, Nekljudova Valentina, Denkert Carsten, Konecny Gottfried E, Kaufmann Manfred, Jackisch Christian, Huober Jens, Hilfrich Jörn, Eiermann Wolfgang, Gerber Bernd, Fasching Peter A, Eidtmann Holger, Costa Serban D, Blohmer Jens-Uwe, Untch Michael, Loibl Sibylle
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer
von Minckwitz G, Blohmer J, Huober J, Hauschild M, Fehm T, Müller B, Denkert C, Loibl S, Nekljudova V, Untch M, German Breast Group, Kunz G, Jackisch C, Gerber B, Eidtmann H, Rezai M, Fasching P, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Kreienberg R, Solbach C, Arbeitsgemeinschaft Gynäkologische Onkologie–Breast Study Groups. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 2012; 366:299-309.
26.01.2012Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer
26.01.2012N Engl J Med 2012; 366:299-309
von Minckwitz Gunter, Blohmer Jens-Uwe, Huober Jens, Hauschild Maik, Fehm Tanja, Müller Berit Maria, Denkert Carsten, Loibl Sibylle, Nekljudova Valentina, Untch Michael, German Breast Group, Kunz Georg, Jackisch Christian, Gerber Bernd, Eidtmann Holger, Rezai Mahdi, Fasching Peter A, Tesch Hans, Eggemann Holm, Schrader Iris, Kittel Kornelia, Hanusch Claus, Kreienberg Rolf, Solbach Christine, Arbeitsgemeinschaft Gynäkologische Onkologie–Breast Study Groups
Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial
Untch M, Gerber B, Rezai M, Jackisch C, Huober J, Kühn T, Nekljudova V, von Minckwitz G, German Breast Group (GBG), Hanusch C, Tesch H, Kreienberg R, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, Blohmer J, Hilfrich J, Strumberg D, Fasching P, Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGO-B) Study Group. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol 2012; 13:135-44.
17.01.2012Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial
17.01.2012Lancet Oncol 2012; 13:135-44
Untch Michael, Gerber Bernd, Rezai Mahdi, Jackisch Christian, Huober Jens, Kühn Thorsten, Nekljudova Valentina, von Minckwitz Gunter, German Breast Group (GBG), Hanusch Claus, Tesch Hans, Kreienberg Rolf, Loibl Sibylle, Bischoff Joachim, Eidtmann Holger, Kaufmann Manfred, Blohmer Jens-Uwe, Hilfrich Jörn, Strumberg Dirk, Fasching Peter A, Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGO-B) Study Group
Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer-results from the GeparQuattro study (GBG 40)
von Minckwitz G, Untch M, Diebold K, Tiemann K, Hoffmann G, Henschen S, Schrader I, Hanusch C, Clemens M, Just M, Dietrich K, Eidtmann H, Holms F, Solbach C, Tesch H, Huober J, Loibl S, Darb-Esfahani S, Denkert C. Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer-results from the GeparQuattro study (GBG 40). Breast Cancer Res Treat 2011
12.06.2011Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer-results from the GeparQuattro study (GBG 40)
12.06.2011Breast Cancer Res Treat 2011
von Minckwitz Gunter, Untch Michael, Diebold Kurt, Tiemann Katharina, Hoffmann Gerald, Henschen Stephan, Schrader Iris, Hanusch Claus, Clemens Michael R, Just Marianne, Dietrich Klaus, Eidtmann Holger, Holms Frank, Solbach Christine, Tesch Hans, Huober Jens, Loibl Sibylle, Darb-Esfahani Silvia, Denkert Carsten
Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy
von Minckwitz G, Zahm D, Khandan F, Hoffmann G, Gerber B, Eidtmann H, Fend F, Dietel M, Mehta K, du Bois A, Blohmer J, Müller B, Loibl S, Budczies J, Hanusch C, Darb-Esfahani S, Hilfrich J, Weiss E, Huober J, Denkert C. Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol 2011; 29:2150-7.
25.04.2011Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy
25.04.2011J Clin Oncol 2011; 29:2150-7
von Minckwitz Gunter, Zahm Dirk-Michael, Khandan Fariba, Hoffmann Gerald, Gerber Bernd, Eidtmann Holger, Fend Falko, Dietel Manfred, Mehta Keyur, du Bois Andreas, Blohmer Jens Uwe, Müller Berit Maria, Loibl Sibylle, Budczies Jan, Hanusch Claus, Darb-Esfahani Silvia, Hilfrich Jörn, Weiss Erich, Huober Jens, Denkert Carsten
Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials
von Minckwitz G, Gerber B, du Bois A, Huober J, Hanusch C, Konecny G, Fett W, Stickeler E, Harbeck N, Müller V, Jackisch C, Hilfrich J, Mehta K, Untch M, Nüesch E, Loibl S, Kaufmann M, Kümmel S, Fasching P, Eiermann W, Blohmer J, Costa S, Jüni P. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat 2010; 125:145-56.
03.11.2010Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials
03.11.2010Breast Cancer Res Treat 2010; 125:145-56
von Minckwitz Gunter, Gerber Bernd, du Bois Andreas, Huober Jens, Hanusch Claus, Konecny Gottfried, Fett Werner, Stickeler Elmar, Harbeck Nadia, Müller Volkmar, Jackisch Christian, Hilfrich Jörn, Mehta Keyur, Untch Michael, Nüesch Eveline, Loibl Sibylle, Kaufmann Manfred, Kümmel Sherko, Fasching Peter A, Eiermann Wolfgang, Blohmer Jens-Uwe, Costa Serban Dan, Jüni Peter
Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial
Witzel I, Untch M, Roller M, Eulenburg C, Barinoff J, Hilfrich J, Just M, Latos K, Tesch H, Lantzsch T, Hauschild M, Henschen S, Hanusch C, Huober J, Mundhenke C, von Minckwitz G, Loibl S, Müller V. Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial. Breast Cancer Res Treat 2010; 123:437-45.
01.09.2010Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial
01.09.2010Breast Cancer Res Treat 2010; 123:437-45
Witzel Isabell, Untch Michael, Roller Marc, Eulenburg Christine Zu, Barinoff Jana, Hilfrich Jörn, Just Marianne, Latos Kunibert, Tesch Hans, Lantzsch Tilmann, Hauschild Maik, Henschen Stephan, Hanusch Claus, Huober Jens, Mundhenke Christoph, von Minckwitz Gunter, Loibl Sibylle, Müller Volkmar
Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study
Huober J, Mehta K, Darb-Esfahani S, Högel B, Thomssen C, Hauschild M, Khandan F, Belau A, Zahm D, Weiss E, Tesch H, Denkert C, von Minckwitz G, Loibl S. Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat 2010; 124:133-40.
10.08.2010Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study
10.08.2010Breast Cancer Res Treat 2010; 124:133-40
Huober Jens, Mehta Keyur, Darb-Esfahani Silvia, Högel Bernhard, Thomssen Christoph, Hauschild Maik, Khandan Fariba, Belau Antje, Zahm Dirk Michael, Weiss Erich, Tesch Hans, Denkert Carsten, von Minckwitz Gunter, Loibl Sibylle
Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial
Riethdorf S, von Minckwitz G, Untch M, Eidtmann H, Tesch H, Holms F, Hilfrich J, Schrader I, Fehm T, Huober J, Roller M, Komor M, Loibl S, Rau T, Zhang L, Müller V, Pantel K. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res 2010; 16:2634-45.
20.04.2010Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial
20.04.2010Clin Cancer Res 2010; 16:2634-45
Riethdorf Sabine, von Minckwitz Gunter, Untch Michael, Eidtmann Holger, Tesch Hans, Holms Frank, Hilfrich Jörn, Schrader Iris, Fehm Tanja, Huober Jens, Roller Marc, Komor Martina, Loibl Sibylle, Rau Thomas, Zhang Liling, Müller Volkmar, Pantel Klaus
Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study
von Minckwitz G, Kühn T, du Bois A, Blohmer J, Thomssen C, Dan Costa S, Jackisch C, Kaufmann M, Mehta K, Hanusch C, Gerber B, Rezai M, Loibl S, Fasching P, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Untch M. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. J Clin Oncol 2010; 28:2015-23.
22.03.2010Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study
22.03.2010J Clin Oncol 2010; 28:2015-23
von Minckwitz Gunter, Kühn Thorsten, du Bois Andreas, Blohmer Jens-Uwe, Thomssen Christoph, Dan Costa Serban, Jackisch Christian, Kaufmann Manfred, Mehta Keyur, Hanusch Claus, Gerber Bernd, Rezai Mahdi, Loibl Sibylle, Fasching Peter A, Huober Jens, Tesch Hans, Bauerfeind Ingo, Hilfrich Jörn, Eidtmann Holger, Untch Michael
Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study
Untch M, Kühn T, du Bois A, Blohmer J, Thomssen C, Dan Costa S, Jackisch C, Kaufmann M, Mehta K, Hanusch C, Gerber B, Rezai M, Loibl S, Fasching P, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, von Minckwitz G. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol 2010; 28:2024-31.
22.03.2010Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study
22.03.2010J Clin Oncol 2010; 28:2024-31
Untch Michael, Kühn Thorsten, du Bois Andreas, Blohmer Jens-Uwe, Thomssen Christoph, Dan Costa Serban, Jackisch Christian, Kaufmann Manfred, Mehta Keyur, Hanusch Claus, Gerber Bernd, Rezai Mahdi, Loibl Sibylle, Fasching Peter A, Huober Jens, Tesch Hans, Bauerfeind Ingo, Hilfrich Jörn, Eidtmann Holger, von Minckwitz Gunter
Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data
Costa S, Tesch H, Gerber B, Baumann K, Thomssen C, Breitbach G, Ibishi S, Jackisch C, Mehta K, Weiss E, Ataseven B, Loibl S, Kaufmann M, Zahm D, Hilfrich J, Huober J, Eidtmann H, du Bois A, Blohmer J, von Minckwitz G. Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010; 28:83-91.
01.01.2010Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data
01.01.2010Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010; 28:83-91
Costa Serban Dan, Tesch Hans, Gerber Bernd, Baumann Klaus H, Thomssen Christoph, Breitbach Georg Peter, Ibishi Shaip, Jackisch Christian, Mehta Keyur, Weiss Erich, Ataseven Beyhan, Loibl Sibylle, Kaufmann Manfred, Zahm Dirk-Michael, Hilfrich Jörn, Huober Jens, Eidtmann Holger, du Bois Andreas, Blohmer Jens-Uwe, von Minckwitz Gunter
Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial
von Minckwitz G, Kaufmann M, Mehta K, Loibl S, Jackisch C, Costa S, Huober J, Gerber B, Hilfrich J, Eidtmann H, Hanusch C, Vogel P, Kümmel S, German Breast Group. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. Journal of the National Cancer Institute 2008; 100:542-51.
16.04.2008Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial
16.04.2008Journal of the National Cancer Institute 2008; 100:542-51
von Minckwitz Gunter, Kaufmann Manfred, Mehta Keyur, Loibl Sibylle, Jackisch Christian, Costa Serban Dan, Huober Jens, Gerber Bernd, Hilfrich Jörn, Eidtmann Holger, Hanusch Claus, Vogel Petra, Kümmel Sherko, German Breast Group
Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study
von Minckwitz G, Kaufmann M, Mehta K, Loibl S, Jackisch C, Costa S, Huober J, Gerber B, Hilfrich J, Eidtmann H, Hanusch C, Vogel P, Kümmel S, German Breast Group. Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. Journal of the National Cancer Institute 2008; 100:552-62.
16.04.2008Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study
16.04.2008Journal of the National Cancer Institute 2008; 100:552-62
von Minckwitz Gunter, Kaufmann Manfred, Mehta Keyur, Loibl Sibylle, Jackisch Christian, Costa Serban Dan, Huober Jens, Gerber Bernd, Hilfrich Jörn, Eidtmann Holger, Hanusch Claus, Vogel Petra, Kümmel Sherko, German Breast Group
Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial
Harter P, Emons G, Pfisterer J, Wollschlaeger K, Meerpohl H, Breitbach G, Tanner B, Sehouli J, Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Committee, Schmalfeldt B, Muenstedt K, Schröder W, du Bois A, Hahmann M, Hasenburg A, Burges A, Loibl S, Gropp M, Huober J, Fink D, AGO Ovarian Cancer Study Group. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Annals of surgical oncology 2006; 13:1702-10.
01.12.2006Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial
01.12.2006Annals of surgical oncology 2006; 13:1702-10
Harter Philipp, Emons Guenter, Pfisterer Jacobus, Wollschlaeger Kerstin, Meerpohl Hans-Gerd, Breitbach Georg-Peter, Tanner Berno, Sehouli Jalid, Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Committee, Schmalfeldt Barbara, Muenstedt Karsten, Schröder Willibald, du Bois Andreas, Hahmann Maik, Hasenburg Annette, Burges Alexander, Loibl Sibylle, Gropp Martina, Huober Jens, Fink Daniel, AGO Ovarian Cancer Study Group